Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis

Cancer Treatment Reviews

Volumn 45, Issue , 2016, Pages 30-37

  Nishijima, Tomohiro F ^a   Muss, Hyman B ^a   Shachar, Shlomit S ^a,b   Moschos, Stergios J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Division of Oncology   (Israel)

Author keywords

Age; Immune checkpoint inhibitor; Immunosenescence; Meta analysis; Overall survival; Progression free survival; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DOCETAXEL; EVEROLIMUS; GLYCOPROTEIN 100; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PLACEBO; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG;

COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; MELANOMA; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; AGE; AGING; CLASSIFICATION; DISEASE FREE SURVIVAL; IMMUNOLOGY; NEOPLASMS; TREATMENT OUTCOME;

AGE FACTORS; AGING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84959346767     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.02.006     Document Type: Review

References (40)

1. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 33(17):1974-1982.
2. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015, 373(16):1490-1492.
3. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
4. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372(4):320-330.
5. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015, 373(2):123-135.
6. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571.
7. Yervoy (ipilimumab) prescribing information. <>. http://packageinserts.bms.com/pi/pi_yervoy.pdf.
8. Nivolumab (Opdivo) prescribing information. <>. http://packageinserts.bms.com/pi/pi_opdivo.pdf.
9. Pembrolizumab (Keytruda) prescribing information. <>. http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
10. Calabro L., Morra A., Fonsatti E., Cutaia O., Fazio C., Annesi D., et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015, 3(4):301-309.
11. Gavazzi G., Krause K.H. Ageing and infection. Lancet Infect Dis 2002, 2(11):659-666.
12. Rosato E., Salsano F. Immunity, autoimmunity and autoimmune diseases in older people. J Biol Regul Homeostat Agents 2008, 22(4):217-224.
13. Pawelec G., Derhovanessian E., Larbi A. Immunosenescence and cancer. Crit Rev Oncol/Hematol 2010, 75(2):165-172.
14. Tomihara K., Curiel T.J., Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncogol 2013, 18(6):573-583.
15. Lim SJ, Kim JM, Lee WS, Kwon WS, Kim TS, Park KH, et al. Immune checkpoint protein expression is up-regulated in tumor-bearing elderly mice. In: Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA [abstr 4055].
16. Castelo-Branco C., Soveral I. The immune system and aging: a review. Gynecol Endocrinol 2014, 30(1):16-22.
17. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62(10):1006-1012.
18. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
20. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
21. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
22. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
23. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.
24. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., Marmol M., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31(5):616-622.
25. Kwon E.D., Drake C.G., Scher H.I., Fizazi K., Bossi A., van den Eertwegh A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15(7):700-712.
26. Ribas A., Puzanov I., Dummer R., Schadendorf D., Hamid O., Robert C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015, 16(8):908-918.
27. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015.
28. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015.
29. Sa S., Qian W., Ellis S., Mason E., Khattak M.A., Gupta A., et al. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res 2015, 25(5):432-442.
30. Berrocal A., Arance A., Lopez Martin J.A., Soriano V., Munoz E., Alonso L., et al. Ipilimumab for advanced melanoma: experience from the spanish expanded access program. Melanoma Res 2014, 24(6):577-583.
31. Ascierto P.A., Simeone E., Sileni V.C., Pigozzo J., Maio M., Altomonte M., et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014, 12:116.
32. Chiarion Sileni V., Pigozzo J., Ascierto P.A., Grimaldi A.M., Maio M., Di Guardo L., et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 2014, 33:30.
33. Mitchell W.A., Lang P.O., Aspinall R. Tracing thymic output in older individuals. Clin Exp Immunol 2010, 161(3):497-503.
34. Naylor K., Li G., Vallejo A.N., Lee W.W., Koetz K., Bryl E., et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005, 174(11):7446-7452.
35. Effros R.B., Walford R.L. The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol 1983, 81(2):298-305.
36. Kubo M., Cinader B. Polymorphism of age-related changes in interleukin (IL) production: differential changes of T helper subpopulations, synthesizing IL 2, IL 3 and IL 4. Eur J Immunol 1990, 20(6):1289-1296.
37. Bloom E.T., Umehara H., Bleackley R.C., Okumura K., Mostowski H., Babbitt J.T. Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice. Eur J Immunol 1990, 20(10):2309-2316.
38. Sharma S., Dominguez A.L., Lustgarten J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 2006, 177(12):8348-8355.
39. Grizzle W.E., Xu X., Zhang S., Stockard C.R., Liu C., Yu S., et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 2007, 128(11-12):672-680.
40. Hurez V., Daniel B.J., Sun L., Liu A.J., Ludwig S.M., Kious M.J., et al. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 2012, 72(8):2089-2099.